Rajiv Agarwal
Indiana University Bloomington
H-index: 101
North America-United States
Top articles of Rajiv Agarwal
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With … | Circulation | Brendon L Neuen Hiddo JL Heerspink Priya Vart Brian L Claggett Robert A Fletcher | 2024/2/6 |
Blocking aldosterone or its receptor—what is the difference? | The Lancet | Rajiv Agarwal | 2024/1/27 |
Effects of SGLT2 inhibitors on cause-specific cardiovascular death in patients with chronic kidney disease: a meta-analysis of CKD progression trials | Clinical Journal of the American Society of Nephrology | Robert A Fletcher William G Herrington Rajiv Agarwal Kaitlin J Mayne Clare Arnott | 2024/1/24 |
Resistant Hypertension in Dialysis: Epidemiology, Diagnosis, and Management | Panagiotis I Georgianos Rajiv Agarwal | 2024/1/17 | |
Cardiovascular Benefits of Potassium-Enriched Salt Substitution: Promises and Challenges of Secondary Analyses | Wanzhu Tu Rajiv Agarwal | 2024/5 | |
The efficacy and safety of reduced-dose oral methylprednisolone in high-risk IgA nephropathy | Kidney International Reports | Dana Kim Jicheng Lv Michelle Hladunewich Vivekanand Jha Lai Seong Hooi | 2024/4/3 |
Introduction: A Multi-Pronged Approach to CKD Associated With Type 2 Diabetes | Ajay K Singh Rajiv Agarwal | 2023/5/1 | |
Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes … | Diabetes Care | Peter Rossing Ellen Burgess Rajiv Agarwal Stefan D Anker Gerasimos Filippatos | 2023/9 |
Kidney and cardiovascular effects of canagliflozin according to age and sex: a post hoc analysis of the CREDENCE randomized clinical trial | American Journal of Kidney Diseases | Tae Won Yi Brendan Smyth Gian Luca Di Tanna Clare Arnott Kathryn Cardoza | 2023/7/1 |
Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials | Kidney Medicine | John M Flack Rajiv Agarwal Stefan D Anker Bertram Pitt Luis M Ruilope | 2023/12/1 |
Overall adverse event profile of vadadustat versus Darbepoetin Alfa for the treatment of anemia associated with chronic kidney disease in phase 3 Trials | American Journal of Nephrology | Rajiv Agarwal Sanjeev Anand Kai-Uwe Eckardt Wenli Luo Patrick S Parfrey | 2023/1/31 |
Effects of finerenone in persons with CKD and T2D are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline. | Diabetes, Obesity & Metabolism | JB McGill R Agarwal SD Anker GL Bakris G Filippatos | 2023/2/1 |
Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes | Journal of Hypertension | Rajiv Agarwal Luis M Ruilope Gema Ruiz-Hurtado Hermann Haller Roland E Schmieder | 2023/2/1 |
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease | European Heart Journal-Cardiovascular Pharmacotherapy | Gerasimos Filippatos Stefan D Anker Bertram Pitt Darren K McGuire Peter Rossing | 2023/1 |
Outcomes with finerenone in participants with stage 4 CKD and type 2 diabetes: a FIDELITY subgroup analysis | Clinical Journal of the American Society of Nephrology | Pantelis Sarafidis Rajiv Agarwal Bertram Pitt Christoph Wanner Gerasimos Filippatos | 2023/5/1 |
Modifiability of composite cardiovascular risk associated with chronic kidney disease in type 2 diabetes with finerenone | JAMA cardiology | Rajiv Agarwal Bertram Pitt Peter Rossing Stefan D Anker Gerasimos Filippatos | 2023/8/1 |
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering | BMJ Open Diabetes Research and Care | David M Charytan Kenneth W Mahaffey Meg J Jardine Christopher P Cannon Bruce Neal | 2023/6/1 |
Hypertension in chronic kidney disease—treatment standard 2023 | Panagiotis I Georgianos Rajiv Agarwal | 2023/12 | |
The nonsteroidal mineralocorticoid-receptor-antagonist finerenone in cardiorenal medicine: a state-of-the-art review of the literature | Panagiotis I Georgianos Rajiv Agarwal | 2023/3/1 | |
Should we CLICK on chlorthalidone for treatment-resistant hypertension in chronic kidney disease? | Rajiv Agarwal | 2023/5 |
Co-Authors
